Directorio

Es posible que algunos contenidos no estén disponibles en español.
473 clinical trials found.
Genitourinary Cancer

We are doing this study to find the most effective, safe dose of an experimental drug called xaluritamig (the study drug). We want to know how well this drug works compared to the standard drugs for people who have metastatic castration-resistant prostate cancer.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital, Duke Raleigh Hospital
Gastrointestinal Cancer

We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.

Compensation: No
Oncology
Digestive System

We are doing this study to learn more about how androgens, a type of sex hormone, might affect women who have nonalcoholic fatty liver disease (NAFLD). We want to see if they play a role in how the disease effects women over time, and we also want to see what role these hormones might play in the relationship between NAFLD and polycystic ovary syndrome.

Compensation: Yes
Ages: 18-42
Non-Oncology
Duke University Hospital
Skin Cancer - Melanoma

We are doing this study to find the most effective, safe dose of a combination of the drugs fianlimab and ceminplimab. We want to know if this combination is an option for people with melanoma. We will compare how well this drug combination works to the usual treatment of relatlimab and nivolumab, which has the brand name Opdualag®.

Compensation: No
Ages: 18-85
Oncology
Duke Raleigh Hospital
Brain and Spine Metastasis

We are doing this study to find out if an experimental drug called APL-5125 (the study drug) is a safe and effective for people with select types of gastrointestinal cancer. We are also trying to find the best dose of APL-5125 to use.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Transplant Medicine

We are doing this study to see if people have the L1 gene called apolipoprotein (APOL1) and to learn how this may affect them.

Compensation: No
Non-Oncology
Blood Disorders

If you join this study, you will be randomly placed into one of two groups. One group will get the study medicine called efgartigimod, and the other group will get a placebo, which is a fake medicine. Both are given through a tube in your vein, called an IV. You will get the medicine or placebo for the first 4 weeks. After that, depending on your platelet count, you will keep getting it every week or every other week for 20 more weeks. After 24 weeks, you may be able to join the next part of the study, where everyone gets the real medicine for up to 52 weeks. If the medicine does not work well enough after 12 weeks, you might be able to switch to the real medicine earlier.

Compensation: Yes
Ages: 18-110
Non-Oncology
Duke University Hospital